Johns Hopkins School of Medicine

Labcorp Appoints Dr. Paul Rothman to Board of Directors

Retrieved on: 
Wednesday, June 7, 2023
Columbia University, Yale University, Partnership, Committee, LH, Research, Leukemia & Lymphoma Society, Organization, Columbia University Irving Medical Center, Johns Hopkins School of Medicine, National academy, National Academy of Medicine, Patient, Merck, NYSE, Research-on-Research Committee, Massachusetts Institute of Technology, Pharmaceutical industry, Nursing, Labcorp

BURLINGTON, N.C., June 7, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent member. Dr. Rothman's appointment is effective June 6, 2023, at which time the Board will expand to 12 directors, 11 of whom are independent.

Key Points: 
  • BURLINGTON, N.C., June 7, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent member.
  • Dr. Rothman's appointment is effective June 6, 2023, at which time the Board will expand to 12 directors, 11 of whom are independent.
  • "I am pleased to announce Dr. Rothman's appointment to our Board of Directors," said Adam Schechter, chairman and chief executive officer (CEO) of Labcorp.
  • He currently chairs the Research Committee on the Board of Directors for Merck and Co., and also serves on the Board of the King Faisal Specialist Hospital and Research Center in Saudi Arabia.

AIxMed Welcomes Barbara Crothers, D.O., as Chief Scientist and Appoints Two Scientific Advisors

Retrieved on: 
Monday, June 5, 2023
ASC, University, College, JPC, Urine, D.O, Consultant, CAP, Cancer, Bladder cancer, Digital Pathology Association, Medicine, University of Pittsburgh School of Medicine, Associate, TPS, DPA, American Society of Cytopathology, Pathology, Artificial intelligence, Department of Defense Veterinary Pathology Residency, Digital, Federation, Health, Wilfrid Sellars, Society, Cell biology, Johns Hopkins School of Medicine, Medical device, Medical imaging, Nursing, AIXM, United States Army, Cytopathology

SANTA CLARA, Calif., June 5, 2023 /PRNewswire/ -- AIxMed, an early-stage smart Cytology company at the intersection of artificial intelligence (AI) and medicine, announced the appointment of Cytopathology industry heavyweight Barbara Crothers, D.O., as Chief Scientist. In this new executive leadership role, Dr. Crothers will drive AIxMed's strategic scientific and clinical initiatives. This includes leading U.S.-based pilot and validation studies of the AIxMed digital Cytology platform.

Key Points: 
  • In this new executive leadership role, Dr. Crothers will drive AIxMed's strategic scientific and clinical initiatives.
  • This includes leading U.S.-based pilot and validation studies of the AIxMed digital Cytology platform.
  • Dr. Crothers is joining in our AI-driven mission to improve workflows and patient care in the battle against cancer.
  • At AIxMed, she will apply these strong credentials towards positioning the Company's technology at the leading edge of the Pathology digital revolution.

Switch Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Pharmaceutical, Health, Carbon, Tissue, Amgen, University of Bristol, University of East London, Migraine, University, Senior, Doctor of Philosophy, Schizophrenia, CSO, P. R. Mallory and Co Inc, Western University, Rochester, Thomas Jefferson University, Pulsus Group, Nitric oxide, Coronavirus Scientific Advisory Board, DRS, Janssen, Physiology, Research, Iron monosilicide, Johns Hopkins School of Medicine, RNA, Genentech, Princeton University, Drexel University, CNS, Conditional, Pain, Discovery, Lilly, Molecular neuroscience, Outline of health sciences, Novo Nordisk, RNA interference, Merck, Therapy, Oligonucleotide, Western University of Health Sciences, Disease, Research fellow, Pharmaceutical industry, Erenumab, Neuroscience, Chemistry, Biology

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.
  • Marc Abrams, David Bredt and James Treanor to our company’s Scientific Advisory Board,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “Together, they bring decades of experience in CNS and RNA therapies and we’re thrilled for them to join the Switch Therapeutics team.
  • Dr. Abrams spent the first 17 years of his career at Merck and Co., Inc in scientific positions of increasing responsibility.

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Retrieved on: 
Tuesday, May 30, 2023
IHL, Clarion, Benzodiazepine, California Institute for Regenerative Medicine, Johns Hopkins School of Medicine, California Institute of Integral Studies, Caffeine, Psychedelic drug, Johns Hopkins University, Patient, Principal, Psilocybin, Emergency medicine, GHB, Principal investigator, Research, Private practice, Certification, Terminal, Cocaine, Psychedelic therapy, The MINDS Foundation, Psychiatry, Cannabis, Addiction, MDA, DPT, NIH, PTSD, Depression, Sunstone, DSM-IV codes, LSD, Alcoholism, Advisory board, Ketamine, Johns Hopkins Center for Health Security, Behavioural sciences, Johns Hopkins, Economics, Yoga, Methamphetamine, ASX, Consciousness, Trust, CQD, Dextromethorphan, Medical director, Episode, MDMA, Pharmaceutical industry, Nursing

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a pharmaceutical company developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and an operator of psychedelic-assisted psychotherapy clinics, is pleased to announce that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.

Key Points: 
  • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.
  • The company is delighted to announce that, in addition to the most experienced psychedelics professionals in Australia taking key executive roles and directorships in the Clarion Clinics Group, three of the world’s most experienced and leading clinical psychedelic experts have joined its Advisory Board.
  • Andrea serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation.
  • I’m grateful for their trust and support.”
    Peter Widdows, Incannex Director, said: “I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team.

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

Retrieved on: 
Tuesday, May 23, 2023
Therapy, Senior, Biotechnology, Ageing, Biomedical Research, Cell, Biomedical engineering, Genentech, Science, Research and development, Patient, Ophthalmology, Engineering, Drug discovery, Tsinghua University, Johns Hopkins School of Medicine, Health, FDA, Notifiable disease, Pharmaceutical industry, Medical device, Research, Medicine

Dr. Yang will be responsible for overseeing the company's research and development efforts and advancing its pipeline of cellular rejuvenation candidates.

Key Points: 
  • Dr. Yang will be responsible for overseeing the company's research and development efforts and advancing its pipeline of cellular rejuvenation candidates.
  • "We are delighted to welcome Dr. Yang to the Life Bio team.
  • Dr. Yang has a track record of building and leading multifunctional R&D teams and advancing early-stage research programs to clinical stage.
  • He has over 20 issued United States patents and has invented platform technologies that led to two FDA-approved drugs.

New Data Reveal Role of SARS-Cov-2 Spike Protein in Covid-19 Associated Coagulopathy

Retrieved on: 
Wednesday, May 24, 2023
Data Management, Biotechnology, Technology, Other Health, Health, Pharmaceutical, Health Technology, Research, Software, Science, COVID-19, Vaccine, Infection, Heart, Vaccination, NRC, Coronavirus, Multimedia, Coagulopathy, Johns Hopkins School of Medicine, LXD, Hypertrophy, Thrombosis, COVID-19 vaccine, Spike S-512, Patient, National Institute on Drug Abuse, Viral, Mouse, Vasoconstriction, AF-2, Spike, Guido Monzino, Medicine

Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation1.

Key Points: 
  • Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation1.
  • This work builds on other recent studies3,4 showing that coagulopathy is clearly associated with the interaction of the SARS-CoV-2 Spike (S) protein with the human Erα.
  • Our data also unravel a new function of the viral protein in direct regulation of thrombosis associated factors.
  • We are excited to identify a path toward further refinement strategies to enable even more powerful benefits through future vaccination and booster initiatives”.

LEADING HEALTHCARE EXECUTIVE RACHEL HOOVER, MS, MBA, NAMED EXECUTIVE VICE PRESIDENT AT UM FACULTY PHYSICIANS, INC.

Retrieved on: 
Friday, May 19, 2023
Proton, Faculty, Patient, Medical Affairs Bureau, UM, University, Education, AUC, UMMS, Physician, University of Maryland, College Park, MBA, Strategic planning, Radiation therapy, State Street Bank and Trust Company, Maryland School, University of Maryland School of Medicine, FPI, Johns Hopkins School of Medicine, University of Maryland Medical Center, Hospital, Isidore, Health, Hoover, Growth, Management, Nursing, MD

Hoover is a healthcare leader with more than 20 years of experience in providing strategic oversight and planning for enterprise-wide initiatives in academic and private health care systems.

Key Points: 
  • Hoover is a healthcare leader with more than 20 years of experience in providing strategic oversight and planning for enterprise-wide initiatives in academic and private health care systems.
  • Most recently she served as Chief Operating Officer for Johns Hopkins Regional Physicians and was previously Director of Global Services for Johns Hopkins Medicine.
  • "I am honored to step into this important role and to work with such an esteemed group of experts," said Ms. Hoover.
  • UMSOM faculty physicians conduct cutting-edge research and clinical trials and offer care in more than 40 medical specialties.

SAIC Announces CEO Transition

Retrieved on: 
Thursday, May 18, 2023
Software, Networks, Other Defense, Technology, Defense, Artificial Intelligence, Science, Engineering, Aerospace, Manufacturing, Other Science, Military, BAM, Army, Comptroller, Lead, Microsoft, SAIC, Economics, Parity, Entrepreneurship, STEM, Keene, Leukemia, NYSE, Princeton University Graduate School, Application, NVTC, Culture, Unisys, Forest Law Enforcement and Governance Program, Renault Alpine GTA/A610, Public sector, Organization, Partnership for Public Service, Russell, Growth, Fiscal, Peace Corps, Government, SHI International Corp, Gerald Loeb Lifetime Achievement Award winners, Public service, Ethics, Family, Workforce, Thurgood Marshall College Fund, CGI Inc., Education, Athena, Public policy, LTG, Stanford University, Johns Hopkins School of Medicine, Black African Students Federation in France, RET, Management, New York University, Fort Moore, Woman, Central Africa

She will succeed Nazzic S. Keene, who has decided to retire as CEO and from the SAIC Board, also effective October 2.

Key Points: 
  • She will succeed Nazzic S. Keene, who has decided to retire as CEO and from the SAIC Board, also effective October 2.
  • To ensure a seamless transition, Townes-Whitley will join SAIC on June 12 as CEO-elect, while Keene continues as CEO through October 1.
  • SAIC Board Chair Donna Morea said, “We thank Nazzic for her tremendous contributions and dedication to SAIC, which resulted in greater opportunities for our employees, improved outcomes for our customers and increased value for our shareholders.
  • “I have known, respected and admired Toni for years and am thrilled to welcome her to our SAIC family,” Keene said.

The Healthcare Innovation Company Announces List of Startup Organizations at thINc360, June 20-22, in Washington, D.C.

Retrieved on: 
Thursday, May 18, 2023
Cloud, CMS, HHS, Centers for Medicare & Medicaid Services, Hospital, United States Department of Health and Human Services, Health equity, JHM, Organization, Medicare, Johns Hopkins School of Medicine, United States Department of Veterans Affairs, Milken Institute, Google Cloud, Novo Nordisk, Optum, Shark Tank, UnitedHealth Group, Television, Content, UHG

BURLINGTON, Mass., May 18, 2023 /PRNewswire-PRWeb/ -- The Healthcare Innovation Company (thINc) announced the initial list of startups that will be participating in its annual thINc360 conference, taking place June 20-22, at the Grand Hyatt in Washington, D.C.

Key Points: 
  • Startup organizations will interact with a panel of investors in a pitch competition that is similar to the popular television show, "Shark Tank."
  • There will also be a "Founder's Forum" sponsored by Stella Technology where founding CEOs will be interviewed on their journeys as health innovators and entrepreneurs.
  • "Startups are the essence of innovation," said Haritha Krishnarathnam, VP of Content and Strategy, thINc.
  • "We are proud to collaborate with such a diverse group of organizations at thINc360.

Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons

Retrieved on: 
Thursday, May 18, 2023
Therapy, Gene, Small RNA, PTC, Coronavirus Scientific Advisory Board, Mutation, RNA, Messenger, Molecular biology, Genetics, Protein, Flagship Pioneering, Patient, Peptide therapeutics, Machine learning, Annual general meeting, Cell, Bloomberg Distinguished Professorships, Biology, American Society of Gene and Cell Therapy, Rare, Oligonucleotide, Society, DSM-IV codes, Johns Hopkins School of Medicine, Vaccine, Fine chemical

"With our unparalleled insights into tRNA biology, we are systematically designing tRNA medicines for Stop Codon Disease to unify the treatment of thousands of rare and common human diseases driven by premature termination codons.

Key Points: 
  • "With our unparalleled insights into tRNA biology, we are systematically designing tRNA medicines for Stop Codon Disease to unify the treatment of thousands of rare and common human diseases driven by premature termination codons.
  • The proof-of-concept data demonstrate that the application of automated high-throughput sequence and ML-driven modification optimization through Alltrna's unique platform can significantly increase engineered tRNA activity.
  • In addition, in a PTC-driven cellular oncology model, Alltrna's engineered tRNA oligonucleotide rescues tumor suppressor activity and downstream function to nearly normal levels, outperforming small molecules for PTC readthrough.
  • Alltrna shows its engineered tRNA oligonucleotide has universal readthrough activity for shared genetic mutations regardless of gene or location in 25 disease models, 14 different genes, and seven different mutation locations on a single gene.